Table 1.

Clinicopathologic and molecular characteristics of colorectal carcinomas harboring AKT1 or PIK3CA mutations

Clinicopathologic parameterAKT1 E17KPIK3CA E542K, E545K/G/DPIK3CA H1047R/L/YPIK3CA R88QAll PIK3CA
Age (range, mean, median)40–76, 57, 5729–90, 58, 5635–85, 62, 6636–68, 58, 5929–90, 59, 58
Sex (M:F)10:839:4312:173:654:66
Proximal location10/18 (56%)32/82 (39%)14/29 (48%)6/9 (67%)52/120 (43%)
Hepatic metastases14/18 (78%)61/82 (74%)10/29 (35%)a,b4/9 (44%)75/120 (63%)
Pulmonary metastases9/18 (50%)24/82 (29%)5/29 (17%)c0/929/120 (24%)c
Mucinous histology7/21 (33%)3/82 (4%)a5/29 (17%)1/9 (11%)9/120 (8%)a
Poor differentiation3/21 (14%)10/82 (12%)10/29 (35%)b2/9 (22%)22/120 (18%)
NRAS or KRAS mutation11/21 (52%)55/82 (67%)13/29 (45%)d3/9 (33%)71/120 (59%)
BRAF V600E mutation7/21 (33%)5/82 (6%)a8/29 (28%)b0/913/120 (11%)a
MSI-H/MMR losse3/17 (18%)10/62 (16%)13/22 (59%)b3/8 (38%)26/92 (28%)
PTEN loss (IHC)6/16 (38%)6/17 (35%)5/15 (33%)11/32 (34%)
p-PRAS40 expression (IHC)10/16 (63%)8/17 (47%)8/15 (53%)16/32 (50%)
  • aP < 0.01, comparison with AKT1 E17K.

  • bP < 0.01, comparison with PIK3CA E542K, E545K/G/D.

  • cP < 0.05, comparison with AKT1 E17K.

  • dP < 0.05, comparison with PIK3CA E542K, E545K/G/D.

  • eThe ratio of IHC to PCR testing (IHC:PCR) to assess MSI-H/MMR status for each PI3K mutation was as follows: AKT1 E17K (4:13), PIK3CA E542K, E545K/G/D (26:36); and PIK3CA H1047R/L/Y (13:9).